邓悦教授基于“剂证对应”理论应用豁痰解毒通络方治疗冠心病经皮冠脉介入术后剩余风险临证经验  

Professor Deng Yue’s clinical experience of applying Huotan Jiedu Tongluo Formula in the treatment of residual risk after percutaneous coronary intervention based on the theory of“dosage and syndrome correspondence”

作　　者：薛雯 邓悦[2] XUE Wen;DEND Yue(College of Traditional Chinese Medicine,Changchun University of Chinese Medicine,Jilin Province,Changchun 130117,China;Cardiovascular Center,the Affiliated Hospital of Changchun University of Chinese Medicine,Jilin Province,Changchun 130021,China)

机构地区：[1]长春中医药大学中医学院,吉林长春130117 [2]长春中医药大学附属医院心病中心,吉林长春130021

出　　处：《中国医药导报》2024年第2期141-144,共4页China Medical Herald

基　　金：国家自然科学基金资助项目(82174350)。

摘　　要：目前中医医生诊治疾病基本遵从“方证对应”原则,但临证时“剂证对应”容易被忽视,本文通过邓悦教授基于“痰瘀伏邪”理论思想应用豁痰解毒通络方治疗冠心病经皮冠脉介入术后合并剩余风险经验分享,从更深的维度分析疾病病因病机,强调了中医药治疗心血管残余风险时,应以改善远期预后、提升患者生存质量为目标,在长期的中药干预过程中,注意用药剂型的调整,有助于治疗该病证时提高临床疗效、降低经济负担。基于此思考,提出针对经皮冠脉介入术术后剩余风险的汤-丸剂序贯治疗中医药方案,旨在为进一步降低动脉粥样硬化性心血管病事件提供临床指导。At present,traditional Chinese medicine doctors basically follow the principle of“formula and syndrome correspondence”in diagnosis and treatment of diseases,but the“dosage and syndrome correspondence”is easily ignored in clinical diagnosis.Based on the theory of“phlegm stasis hidden pathogen”,Professor Deng Yue shares the experience of applying Huotan Jiedu Tongluo Formula in the treatment of residual risk after percutaneous coronary intervention for coronary heart disease,and analyzes the causes and pathogenesis of the disease from a deeper dimension,and stresses that the goal of improving long-term prognosis and quality of life of patients should be taken as the goal when traditional Chinese medicine is used to treat residual cardiovascular risk.Paying attention to the adjustment of dosage forms is helpful to improve clinical efficacy and reduce economic burden in the treatment of this disease.Based on this consideration,the sequential treatment plan of traditional Chinese medicine with decoction-pills for residual risk after percutaneous coronary intervention is proposed,aiming at providing clinical guidance for further reducing atherosclerotic cardiovascular disease events.

关 键 词：痰瘀伏邪 经皮冠脉介入术 剩余风险 中医药 剂证对应 

分 类 号：R541.4[医药卫生—心血管疾病] R289[医药卫生—内科学]